FEATURED CONTRIBUTED CONTENT

New White Paper Highlights: Mars vs. Venus: Men, Women, Trust & Biopharma


New White Paper Highlights: Mars vs. Venus: Men, Women, Trust & Biopharma

This new white paper covers how men and women think about the biopharma industry, specifically in the area of trust. The white paper summarizes two surveys that compare and contrast the thoughts of men and women. The findings are quite interesting. Here are some of the highlights. Pharma is ranked below the average industry in terms […]

July 14, 2016More Clinical »
Enhancing the Patient Experience through mHealth – a Win-win


Enhancing the Patient Experience through mHealth – a Win-win

In less than five years, mHealth has evolved from a futurist’s bold idea to the new normal. Studies are implementing patient- and site-facing apps and reaping the rewards today. We know that mHealth technologies are arrows in a sponsor’s patient-centric quiver – and that strategies that include them see improved engagement, more reliable data and higher retention rates. Yet […]

July 18, 2016More Clinical »
Regulatory Application of Standard for Exchange of Nonclinical Data (SEND)


Regulatory Application of Standard for Exchange of Nonclinical Data (SEND)

Standard for Exchange of Nonclinical Data (SEND) is a new formatting requirement for the submission of electronic data to the FDA. This initiative is led by the Clinical Data Interchange Standards Consortium (CDISC) with the intent to integrate clinical Study Data Tabulation Models (SDTM) into nonclinical data submissions. SEND creates structured organization and terminology for […]

April 19, 2016More Clinical »
No Patient Left Behind – Connecting Rare Disease Patients to Orphan Drug Manufacturers


No Patient Left Behind – Connecting Rare Disease Patients to Orphan Drug Manufacturers

If you have ever worked with Orphan Drugs, you know finding appropriate patients is a major commercial challenge. Pharmaceutical sponsors of Orphan Drugs often lack the infrastructure and capabilities necessary to identify physicians who diagnose, treat, and manage these rare patients. There are many challenges facing the Orphan Drug category: Multiple healthcare providers and specialties […]

July 28, 2016More Clinical »
Mars vs. Venus: Men, Women, Trust & Biopharma


Mars vs. Venus: Men, Women, Trust & Biopharma

Do men and women trust the biopharmaceutical industry? How do the genders agree and disagree on this topic?  The results of two recent surveys paint a concerning picture, yet also show ways the industry can impact these opinions. This analysis reveals how men and women prefer to engage with healthcare organizations and presents a roadmap […]

July 6, 2016More Clinical »
PharmaVOICE 100 Celebration Tickets 2016 Available Now


PharmaVOICE 100 Celebration Tickets 2016 Available Now

The PharmaVOICE 100 Celebration convenes the most influential and inspirational leaders from across all sectors of the life-sciences industry. PharmaVOICE’s unique positioning allows us to bring together these leaders in a distinctive format allowing for much-needed collaboration through sharing ideas, insights, and business perspectives, while offering the opportunity to expand personal and professional networks. Thursday […]

June 21, 2016More Clinical »
Overcoming the Business Challenges of Rare Diseases


Overcoming the Business Challenges of Rare Diseases

In this episode, Michael Carlin of TrialCard discusses rare diseases and orphan drugs, and how life sciences companies can overcome the many business challenges associated with these types of disease states. There is also a related white paper entitled “No Patient Left Behind – Connecting Rare Disease Patients to Orphan Drug Manufacturers.” Use the download link […]

July 28, 2016More Clinical »
FEEDBACK